AR050467A1 - Sales de lercanidipina - Google Patents

Sales de lercanidipina

Info

Publication number
AR050467A1
AR050467A1 ARP050103516A ARP050103516A AR050467A1 AR 050467 A1 AR050467 A1 AR 050467A1 AR P050103516 A ARP050103516 A AR P050103516A AR P050103516 A ARP050103516 A AR P050103516A AR 050467 A1 AR050467 A1 AR 050467A1
Authority
AR
Argentina
Prior art keywords
lercanidipine
acids
acid
salts
counter
Prior art date
Application number
ARP050103516A
Other languages
English (en)
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Publication of AR050467A1 publication Critical patent/AR050467A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Sales de adicion que comprenden lercanidipina y un contra-ion ácido seleccionado del grupo que consiste en un contra-ion ácido seleccionado del grupo que consiste en: (i) ácidos inorgánicos, (ii) ácidos sulfonicos, (iii) ácidos monocarboxílicos, (iv) ácidos dicarboxílicos, (v) ácidos tricarboxílicos, y (vi) sulfonimidas aromáticas, con la condicion que dicho contra-ion ácido no sea ácido clorhídrico. En concreto, tanto las sales amorfas como las cristalinas de lercanidipina con ácido benzenosulonico y ácido naftaleno-1,5-disulonico han revelado ser sales amorfas de lercanidipina con otros varios contra-iones ácidos
ARP050103516A 2004-08-24 2005-08-22 Sales de lercanidipina AR050467A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60414904P 2004-08-24 2004-08-24

Publications (1)

Publication Number Publication Date
AR050467A1 true AR050467A1 (es) 2006-10-25

Family

ID=35159792

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103516A AR050467A1 (es) 2004-08-24 2005-08-22 Sales de lercanidipina

Country Status (19)

Country Link
US (1) US7683179B2 (es)
EP (1) EP1799644B1 (es)
JP (1) JP2008510754A (es)
KR (1) KR20070045351A (es)
CN (1) CN101048379A (es)
AR (1) AR050467A1 (es)
AU (1) AU2005276619B2 (es)
BR (1) BRPI0514606A (es)
CA (1) CA2575078A1 (es)
EA (1) EA011773B1 (es)
ES (1) ES2462921T3 (es)
IL (1) IL180905A0 (es)
MX (1) MX2007002141A (es)
NO (1) NO20071515L (es)
NZ (1) NZ553127A (es)
PE (1) PE20060629A1 (es)
TW (1) TW200613275A (es)
WO (1) WO2006021397A1 (es)
ZA (1) ZA200702364B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1953162B9 (de) * 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo
AR053023A1 (es) * 2005-02-25 2007-04-18 Recordati Ireland Ltd Base libre de lercanidipina, metodos para su preparacion y composiciones farmaceuticas que las contienen
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
AU2007247190A1 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Polymorphs
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
MY147013A (en) 2006-06-12 2012-10-15 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
WO2008040367A1 (en) * 2006-08-01 2008-04-10 Union Quimico-Farmaceutica S.A. Lercanidipine hydrobromide, a process for its preparation, crystalline forms and compositions thereof
US20080175872A1 (en) * 2006-09-28 2008-07-24 Osmotica Corp. Controlled Release Dosage Form Containing Lercanidipine and a Performance-enhancing Acid
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
US20080234516A1 (en) * 2007-03-14 2008-09-25 Valerie Niddam-Hildesheim Processes for preparing solid states of O-desmethylvenlafaxine succinate
WO2009017813A1 (en) * 2007-08-02 2009-02-05 Teva Pharmaceutical Industries Ltd. O-desmethyl venlafaxine saccharinate
KR20100074303A (ko) 2007-11-26 2010-07-01 테바 파마슈티컬 인더스트리즈 리미티드 Ｏ-데스메틸벤라팍신 푸마레이트의 결정형
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
JP5674660B2 (ja) * 2008-08-01 2015-02-25 ザ メディシンズ カンパニー 医薬組成物および不純物の濃度が低い医薬組成物の製造方法
US20100105743A1 (en) * 2008-08-01 2010-04-29 Gopal Krishna Pharmaceutical compositions and methods for stabilizing the same
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
JP2012502081A (ja) 2008-09-10 2012-01-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連症状の治療のための組み合わせ治療
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
CA2795023A1 (en) * 2010-03-29 2011-10-06 Pliva Hrvatska D.O.O. Crystal forms of o-desmethylvenlafaxine fumarate
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin
WO2023219106A1 (ja) * 2022-05-10 2023-11-16 Ｍｙｒｏｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 ２－メチル－２－チアゾリンの塩

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8403866D0 (en) * 1984-02-14 1984-03-21 Recordati Chem Pharm Diphenylalkylaminoalkyl esters
IT1275532B (it) * 1995-07-14 1997-08-07 Recordati Chem Pharm Uso di derivati 1,4-diidropiridinici per la prevenzione e la terapia della degenerazione aterosclerotica della parete arteriosa
US5696139A (en) 1995-05-12 1997-12-09 Recordati S.A., Chemical And Pharmaceutical Company Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure
US5767136A (en) 1995-05-12 1998-06-16 Recordati, S.A. Chemical And Pharmaceutical Company 1,4-Dihydropyridines useful for prevention or reduction of atherosclerotic lesions on arterial walls
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US20030069285A1 (en) 2001-08-06 2003-04-10 Recordati Ireland Limited Novel solvate and crystalline forms of lercanidipine hydrochloride
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
US6699892B2 (en) * 2002-06-04 2004-03-02 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salt of amlodipine and method of preparing the same
AU2003274004A1 (en) * 2002-10-16 2004-05-04 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Also Published As

Publication number Publication date
AU2005276619B2 (en) 2009-04-30
CN101048379A (zh) 2007-10-03
WO2006021397A8 (en) 2006-04-27
ES2462921T3 (es) 2014-05-26
US20060047125A1 (en) 2006-03-02
KR20070045351A (ko) 2007-05-02
EP1799644A1 (en) 2007-06-27
PE20060629A1 (es) 2006-08-11
MX2007002141A (es) 2007-04-27
TW200613275A (en) 2006-05-01
CA2575078A1 (en) 2006-03-02
BRPI0514606A (pt) 2008-06-17
AU2005276619A1 (en) 2006-03-02
EP1799644B1 (en) 2014-02-12
JP2008510754A (ja) 2008-04-10
IL180905A0 (en) 2007-07-04
US7683179B2 (en) 2010-03-23
WO2006021397A1 (en) 2006-03-02
NO20071515L (no) 2007-05-22
EA011773B1 (ru) 2009-06-30
ZA200702364B (en) 2008-09-25
NZ553127A (en) 2009-07-31
EA200700492A1 (ru) 2007-08-31

Similar Documents

Publication Publication Date Title
AR050467A1 (es) Sales de lercanidipina
AR076027A1 (es) Metodos e intermediarios para la preparacion de agentes farmaceuticos
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
AR075243A1 (es) Derivados del 1-fenil-2-piridinil alquil alcohol como inhibidores de fosfodiesterasa
EA201070966A1 (ru) Фолаты, композиции и применение указанных композиций
EA201171329A1 (ru) Твердый препарат
EA201200038A1 (ru) Новые соли ацетилсалициловой кислоты
RU2012151152A (ru) Твердая композиция терефталевой кислоты
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EA201390491A1 (ru) Производные 1,4-оксазепана
RU2008105019A (ru) N-замещенные 4-метил-2,6-дихлорникотиноил-мочевины в качестве антидотов 2,4-д на подсолнечнике
BRPI0919996A2 (pt) processo para produzir um ácido dicarboxílico aromático.
UY29083A1 (es) Sales de lercanidipina
PA8796701A1 (es) Nuevas sales de adicion de inhibidores de la enzima de conversion de la angiotensina a acidos donadores de no su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
EA201300142A1 (ru) Производные 1,4-дигидропиридина, обладающие противовирусной эффективностью
AR110242A1 (es) Composición ácida para el tratamiento de ácidos grasos
AR087993A1 (es) Procesos e intermediarios para la preparacion de un inhibidor macrociclico de la proteasa del hcv
TH107922A (th) การเพิ่มเสถียรภาพของไดเอสเทอร์ของกรดไดคาร์บอนิก
TH155129A (th) อนุพันธ์ของกรด 1-อะมิโน-2-ไซโคลโพรพิลเอทิลโบโรนิก
RU2010123283A (ru) Буферная жидкость
TH108942B (th) เกลือของตัวยับยั้งเอนไซม์ชนิดใหม่นอกจากนั้นที่เปลี่ยนแองจิโอเทนซินด้วยกรดตัวให้ no กระบวนการเตรียมเกลือชนิดเหล่านั้นและองค์ประกอบที่เป็นเภสัชภัณฑ์ที่มีเกลือชนิดเหล่านั้น
TH105092A (th) อนุพันธ์เบนโซควินาโซลีน
TH108764A (th) สารผสมที่ทำความสะอาดผม
TH110956A (th) สารผสมอาหารเสถียรต่อการเก็บและกระบวนการสำหรับการเตรียมของมัน
TH123652B (th) อนุพันธ์กรดลิโพอิก

Legal Events

Date Code Title Description
FA Abandonment or withdrawal